The first head-to-head superiority study of Cimzia and Humira, two treatments in the anti-tumor necrosis factor (TNF) class has failed to demonstrate that either is superior. The phase 4 study compared certolizumab pegol (Cimzia, UCB) plus methotrexate (MTX) with adalimumab (Humira, AbbVie) plus MTX in adults with moderate-to-severe rheumatoid arthritis (RA) who were inadequate responders to MTX.

The percentages of patients achieving a 20% improvement in the symptoms of RA, as defined by the American College of Rheumatology, at three months were 69% for certolizumab and 71% for adalimumab, and the percentages of patients achieving a state of low disease activity at two years were 36% and 34%, respectively.

Click here to read more